Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Public ClinicalTrials.gov record NCT04025632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.
Study identification
- NCT ID
- NCT04025632
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2019 (Actual)
- Primary completion
- Mar 4, 2021 (Actual)
- Completion
- Jun 14, 2021 (Actual)
- Last update posted
- Jul 27, 2022
2019 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| University of California Irvine | Orange | California | 92868 | — |
| University of Florida Health Jacksonville | Jacksonville | Florida | 32209 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| National Institute of Health | Bethesda | Maryland | 20892 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Washington University School of Medicine in Saint Louis | St Louis | Missouri | 63110 | — |
| Northwell Health Neuroscience Institute | Great Neck | New York | 11021 | — |
| The Ohio State University | Columbus | Ohio | 43221 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Wesley Neurology Clinic | Memphis | Tennessee | 38018 | — |
| Austin Neuromuscular Center | Austin | Texas | 78756 | — |
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04025632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2022 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04025632 live on ClinicalTrials.gov.